Cholesteryl Ester Transfer Protein (CETP) inhibitors and their role in cardiovascular disorders

Drugs of the Future

Volumn 36, Issue 5, 2011, Pages 377-384

  Kontush, Anatol ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANACETRAPIB; APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; STATIN; TORCETRAPIB;

ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG FATALITY; DRUG POTENCY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEADACHE; HUMAN; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW;

EID: 84952989157     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.05.1600192     Document Type: Review

References (75)

1. Chapman, M.J. Beyond LDL-cholesterol reduction: The way ahead in managing dyslipidaemia. Eur Heart J Suppl 2005, 7(F): F56-62.
2. Yusuf, S., Hawken, S., Ounpuu, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004, 364(9438): 937-52. (Pubitemid 39208455)
3. Barter, P., Gotto, A.M., LaRosa, J.C. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357(13): 1301-10. (Pubitemid 47481452)
4. Remaley, A.T., Amar, M., Sviridov, D. HDL-replacement therapy: Mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther 2008, 6(9): 1203-15.
5. Kontush, A., Chapman, M.J. Functionally defective HDL: A new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 2006, 3(58): 342-74. (Pubitemid 44394906)
6. Chapman, M.J., Le Goff, W., Guerin, M., Kontush, A. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31(2): 149-64.
7. Le Goff, W., Guerin, M., Chapman, M.J. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004, 101(1): 17-38. (Pubitemid 38068523)
8. Wang, A., Prouty, C.P., Pelton, P.D., Yong, M., Demarest, K.T., Murray, W.V., Kuo, G.H. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[ 1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors. Bioorg Med Chem Lett 2010, 20(4): 1432-5.
9. Rano, T.A., Sieber-McMaster, E., Pelton, P.D., Yang, M., Demarest, K.T., Kuo, G.H. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett 2009, 19(9): 2456-60.
10. Kallashi, F., Kim, D., Kowalchick, J. et al. 2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice. Bioorg Med Chem Lett 2011, 21(1): 558-61.
11. Abu Sheikha, G., Abu Khalaf, R., Melhem, A., Albadawi, G. Design, synthesis, and biological evaluation of benzylamino-methanone based cholesteryl ester transfer protein inhibitors. Molecules 2010, 15(8): 5721-33.
12. Clark, R.W., Sutfin, T.A., Ruggeri, R.B. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24(3): 490-7. (Pubitemid 38326143)
13. Brousseau, M.E., Schaefer, E.J., Wolfe, M.L. et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350(15): 1505-15. (Pubitemid 38477775)
14. Catalano, G., Julia, Z., Frisdal, E. et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29(2): 268-75.
15. Brousseau, M.E., Diffenderfer, M.R., Millar, J.S. et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25(5): 1057-64. (Pubitemid 40627855)
16. Brousseau, M.E., Millar, J.S., Diffenderfer, M.R. et al. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. J Lipid Res 2009, 50(7): 1456-62.
17. Millar, J.S., Brousseau, M.E., Diffenderfer, M.R. et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 2006, 26(6): 1350-6. (Pubitemid 44305381)
18. De Grooth, G.J., Kuivenhoven, J.A., Stalenhoef, A.F. et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study. Circulation 2002, 105(18): 2159-65. (Pubitemid 34517159)
19. Kuivenhoven, J.A., De Grooth, G.J., Kawamura, H., Klerkx, A.H., Wilhelm, F., Trip, M.D., Kastelein, J.J.P. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005, 95(9): 1085-8. (Pubitemid 40544314)
20. Bisoendial, R.J., Hovingh, G.K., El Harchaoui, K. et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 2005, 25(9): e133-4.
21. Stein, E.A., Stroes, E.S., Steiner, G. et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009, 104(1): 82-91.
22. Stein, E.A., Roth, E.M., Rhyne, J.M., Burgess, T., Kallend, D., Robinson, J.G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): Results from a 48-week trial. Eur Heart J 2010, 31(4): 480-8.
23. Hermann, F., Enseleit, F., Spieker, L.E. et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res 2009, 123(3): 460-5.
24. Krishna, R., Anderson, M.S., Bergman, A.J. et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370(9603): 1907-14. (Pubitemid 350192656)
25. Bloomfield, D., Carlson, G.L., Sapre, A. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157(2): 352-60 e2.
26. Cannon, C.P., Shah, S., Dansky, H.M. et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363(25): 2406-15.
27. Ranalletta, M., Bierilo, K.K., Chen, Y. et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010, 51(9): 2739-52.
28. Niesor, E.J., Von der Marck, E., Brousse, M., Maugeais, C. Inhibition of cholesteryl ester transfer protein (CETP): Different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR). Atherosclerosis 2008, 199(1): 231-59.
29. Niesor, E.J., Magg, C., Ogawa, N. et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010, 51(12): 3443-54.
30. Maugeais, C., Magg, C., Dernick, G. et al. Dalcetrapib binds to and changes the conformation of CETP in a unique manner (differing to that observed with torcetrapib). Circulation 2009, 120(18, Suppl.): S445.
31. Barter, P.J., Caulfield, M., Eriksson, M. et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21): 2109-22. (Pubitemid 350146106)
32. Vergeer, M., Bots, M.L., Van Leuven, S.I. et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008, 118(24): 2515-22.
33. Sirtori, C.R., Mombelli, G. Viability of developing CETP inhibitors. Cardiovasc Ther 2008, 26(2): 135-46. (Pubitemid 351945132)
34. Joy, T., Hegele, R.A. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008, 7(2): 143-55. (Pubitemid 351194062)
35. Kontush, A., Guerin, M., Chapman, M.J. Spotlight on HDL-raising therapies: Insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008, 5(6): 329-36. (Pubitemid 351761707)
36. Blasi, E., Bamberger, M., Knight, D. et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J Cardiovasc Pharmacol 2009, 53(6): 507-16.
37. Chapman, M.J. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006, 111(3): 893-908. (Pubitemid 44164383)
38. Forrest, M.J., Bloomfield, D., Briscoe, R.J. et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008, 154(7): 1465-73.
39. Krikken, J.A., Dallinga-Thie, G.M., Navis, G., Dullaart, R.P. Reninangiotensin- aldosterone responsiveness to low sodium and blood pressure reactivity to angiotensin-II are unrelated to cholesteryl ester transfer protein mass in healthy subjects. Expert Opin Ther Targets 2008, 12(11): 1321-8.
40. Sofat, R., Hingorani, A.D., Smeeth, L. et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010, 121(1): 52-62.
41. Kastelein, J.J., Van Leuven, S.I., Burgess, L. et al.; RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356(16): 1620-30. (Pubitemid 46631671)
42. Nissen, S.E., Tardif, J.C., Nicholls, S.J. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356(13): 1304-16. (Pubitemid 46513296)
43. Nicholls, S.J., Brennan, D.M., Wolski, K., Kalidindi, S.R., Moon, K.-W., Tuzcu, E.M., Nissen, S.E. Changes in levels of high density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: Insights from ILLUSTRATE. Circulation 2007, 116(16, Suppl.): II-127.
44. Nicholls, S.J., Tuzcu, E.M., Brennan, D.M., Tardif, J.C., Nissen, S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008, 118(24): 2506-14.
45. Thompson, A., Di Angelantonio, E., Sarwar, N. et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299(23): 2777-88. (Pubitemid 351846853)
46. Regieli, J.J., Jukema, J.W., Grobbee, D.E. et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: An adverse pharmacogenetic interaction. Eur Heart J 2008, 29(22): 2792-9.
47. Wilson, P.W. CETP genes, metabolic effects, and coronary disease risk. JAMA 2008, 299(23): 2795-6. (Pubitemid 351846856)
48. Boekholdt, S.M., Sacks, F.M., Jukema, J.W. et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: Individual patient metaanalysis of 13,677 subjects. Circulation 2005, 111(3): 278-87. (Pubitemid 40165333)
49. Boekholdt, S.M., Kuivenhoven, J.A., Wareham, N.J. et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: The prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004, 110(11): 1418-23. (Pubitemid 39238020)
50. De Grooth, G.J., Smilde, T.J., Van Wissen, S. et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004, 173(2): 261-7. (Pubitemid 38469794)
51. Vasan, R.S., Pencina, M.J., Robins, S.J., Zachariah, J.P., Kaur, G., D'Agostino, R.B., Ordovas, J.M. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120(24): 2414-20.
52. Ritsch, A., Scharnagl, H., Eller, P. et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2010, 121(3): 366-74.
53. Khera, A.V., Wolfe, M.L., Cannon, C.P., Qin, J., Rader, D.J. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapythrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol 2010, 106(4): 451-6.
54. Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., Shinkai, H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406(6792): 203-7. (Pubitemid 30469005)
55. Morehouse, L.A., Sugarman, E.D., Bourassa, P.-A. et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007, 48(6): 1263-72. (Pubitemid 47312028)
56. Sugano, M., Makino, N., Sawada, S. et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998, 273(9): 5033-6. (Pubitemid 28108660)
57. Rittershaus, C.W., Miller, D.P., Thomas, L.J. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20(9): 2106-12.
58. Rader, D.J. Illuminating HDL - Is it still a viable therapeutic target? N Engl J Med 2007, 357(21): 2180-3. (Pubitemid 350146114)
59. Guerin, M., Dolphin, P.J., Chapman, M.J. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb 1994, 14(5): 679-85.
60. Guerin, M., Le Goff, W., Duchene, E. et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 2008, 28(1): 148-54.
61. Yvan-Charvet, L., Matsuura, F., Wang, N. et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27(5): 1132-8. (Pubitemid 46641969)
62. Yvan-Charvet, L., Kling, J., Pagler, T. et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010, 30(7): 1430-8.
63. Thuahnai, S.T., Lund-Katz, S., Dhanasekaran, P. et al. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J Biol Chem 2004, 279(13): 12448-55.
64. Kobayashi, J., Okamoto, H., Otabe, M., Bujo, H., Saito, Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis 2002, 162(1): 131-5. (Pubitemid 34327350)
65. Rhainds, D., Brodeur, M., Lapointe, J., Charpentier, D., Falstrault, L., Brissette, L. The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters. Biochemistry 2003, 42(24): 7527-38. (Pubitemid 36735830)
66. Burillo, E., Andres, E.M., Mateo-Gallego, R., Fiddyment, S., Jarauta, E., Cenarro, A., Civeira, F. Increase in high-density lipoprotein cholesterol is not related with higher non-cardiovascular mortality; systematic review and meta-regression analysis. Circulation 2009, 120(18, Suppl.): S406.
67. Connelly, M.A., Parry, T.J., Giardino, E.C. et al. Torcetrapib produces endothelial dysfunction independent of CETP inhibition. J Cardiovasc Pharmacol 2010, 55(5): 459-68.
68. Kontush, A., Chapman, M.J. Antiatherogenic small, dense HDL - Guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3(3): 144-53.
69. Duriez, P. CETP inhibition. Lancet 2007, 370(9603): 1882-3. (Pubitemid 350192639)
70. Clark, R.W., Cunningham, D., Cong, Y. et al. Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection. J Lipid Res 2010, 51(5): 967-74.
71. Kontush, A., Chapman, M.J. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008, 8(1): 51-9. (Pubitemid 351384876)
72. Patel, S., Puranik, R., Nakhla, S. et al. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 2009, 204(2): 424-8.
73. Cannon, C.P., Dansky, H.M., Davidson, M. et al. Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 2009, 158(4): 513-9.
74. Schwartz, G.G., Olsson, A.G., Ballantyne, C.M. et al. Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009, 158(6): 896-901.
75. Robinson, J.G. Dalcetrapib: A review of phase II data. Expert Opin Investig Drugs 2010, 19(6): 795-805.